ID   888-mel
AC   CVCL_4632
SY   888-MEL; 888 mel; 888mel; 888MEL; 888; Mel888; mel888; MG-888
DR   BTO; BTO:0002950
DR   EFO; EFO_0006531
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_4632
DR   CGH-DB; 9308-4
DR   Cosmic; 876679
DR   Cosmic; 877281
DR   Cosmic; 905221
DR   Cosmic; 1042621
DR   Cosmic; 1238108
DR   Cosmic; 1303045
DR   EGA; EGAS00001000610
DR   GEO; GSM206439
DR   GEO; GSM218046
DR   GEO; GSM274691
DR   GEO; GSM1092556
DR   GEO; GSM1507930
DR   PharmacoDB; 888mel_32_2019
DR   Progenetix; CVCL_4632
DR   Wikidata; Q54605471
RX   PubMed=8027550;
RX   PubMed=8081556;
RX   PubMed=8537970;
RX   PubMed=9598804;
RX   PubMed=9670966;
RX   PubMed=10048982;
RX   PubMed=10754339;
RX   PubMed=15467732;
RX   PubMed=16470173;
RX   PubMed=18172304;
RX   PubMed=25485619;
RX   PubMed=25502142;
RX   PubMed=25538140;
WW   http://www.ott.nih.gov/erma/metastatic-melanoma-cancer-cell-line-888-mel
CC   From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01,24; B*52,55; C*01:02,12:01 (PubMed=9670966).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Oral cavity, soft palate, hypodermis; UBERON=UBERON_0001733+UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7943 ! 1290-mel
OI   CVCL_DI11 ! 1858-mel a
OI   CVCL_DI12 ! 1858-mel b
OI   CVCL_DI13 ! 1858-mel c
OI   CVCL_DI14 ! 1936-mel
OI   CVCL_DI15 ! 1962-mel
OI   CVCL_A1DN ! 888-EBV
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 28
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=8081556; DOI=10.1097/00002371-199407000-00002;
RA   Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A.,
RA   O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J.,
RA   Rosenberg S.A.;
RT   "Locus-specific analysis of human leukocyte antigen class I expression
RT   in melanoma cell lines.";
RL   J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994).
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=16470173; DOI=10.1038/sj.jid.5700193;
RA   Wang E., Voiculescu S., Le Poole I.C., El-Gamil M., Li X.,
RA   Sabatino M., Robbins P.F., Nickoloff B.J., Marincola F.M.;
RT   "Clonal persistence and evolution during a decade of recurrent
RT   melanoma.";
RL   J. Invest. Dermatol. 126:1372-1377(2006).
//
RX   PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939;
RA   Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F.,
RA   Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.;
RT   "Conservation of genetic alterations in recurrent melanoma supports
RT   the melanoma stem cell hypothesis.";
RL   Cancer Res. 68:122-131(2008).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25502142; DOI=10.1038/ncomms6712;
RA   Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C.,
RA   Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H.,
RA   Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G.,
RA   Graeber T.G., Ribas A., Lo R.S., Peeper D.S.;
RT   "Low MITF/AXL ratio predicts early resistance to multiple targeted
RT   drugs in melanoma.";
RL   Nat. Commun. 5:5712.1-5712.15(2014).
//
RX   PubMed=25538140; DOI=10.15252/msb.20145450;
RA   Smit M.A., Maddalo G., Greig K., Raaijmakers L.M., Possik P.A.,
RA   van Breukelen B., Cappadona S., Heck A.J.R., Altelaar A.F.M.,
RA   Peeper D.S.;
RT   "ROCK1 is a potential combinatorial drug target for BRAF mutant
RT   melanoma.";
RL   Mol. Syst. Biol. 10:772-772(2014).
//